Dorsey Wright & Associates’s GT Biopharma GTBP Stock Holding History

Dorsey Wright & Associates’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-81	Closed	-$38K	–	301
2021 Q2	$38K	Buy	+81	New	+$33.7K	0.01%	265

Other funds holding GTBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCP

Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return

Dorsey Wright & Associates's GTBP Position: Q3 2021 in Review

Dorsey Wright & Associates sold out of GT Biopharma (GTBP) in Q3 2021, closing a stake of 81 shares — an estimated $38K sold.

Dorsey Wright & Associates first reported a position in GTBP in Q2 2021 and held it in 1 quarter. The position peaked at $38K in Q2 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q3 2021.

Dorsey Wright & Associates reported no remaining GT Biopharma position as of Q3 2021 after selling out during the quarter.
Dorsey Wright & Associates sold 81 GT Biopharma shares in Q3 2021, an estimated $38K.
Dorsey Wright & Associates first reported a position in GT Biopharma in Q2 2021 and held it in 1 quarter.
Dorsey Wright & Associates's GT Biopharma position peaked at $38K in Q2 2021.
53 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2021.

Based on Dorsey Wright & Associates's 13F filing for Q3 2021, filed 26 Oct 2021.